Timothy J Pluard MD

Breast Cancer

Koontz Endowed Chair in Breast Disease, University of Missouri, Kansas City School of Medicine. Director Saint Luke's Cancer Institute

Join to View Full Profile

4401 Wornall RdKansas City, MO 64111
Phone+1 816-932-3800
Fax+1 816-932-3888

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1991 - 1993
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1987 - 1991
Washington University in St. Louis School of MedicineClass of 1987

Certifications & Licensure

MO State Medical License 1993 - 2026
KS State Medical License 2014 - 2024
FL State Medical License 2020 - 2022
TX State Medical License 1988 - 1992
American Board of Internal Medicine Medical Oncology

Clinical Trials

Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer Start of enrollment: 2011 Sep 01
Terminated
Phase 2
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer Start of enrollment: 2013 Jan 10
Terminated
Phase 3
Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy Start of enrollment: 2013 Apr 04
Terminated
Not Applicable
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2013 Dec 17
COMPLETED
PHASE3
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
ACTIVE_NOT_RECRUITING
PHASE3
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer Start of enrollment: 2018 Jul 06
Completed
Phase 2
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Start of enrollment: 2022 Mar 07
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Contact, Principal Investigator
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Start of enrollment: 2023 Oct 31
RECRUITING
PHASE3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results fro...
Santiago Escrivá-de-Romani, Juan M Cejalvo, Emilio Alba, Jennifer Friedmann, Álvaro Rodríguez-Lescure
The Lancet. Oncology. 2025-06-01
1 citations
Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.
Shari B Goldfarb, Sarah L Sammons, Jane L Meisel, Timothy J Pluard, Simon N Jenkins
Clinical Breast Cancer. 2025-04-01
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocri...
Lowell L Hart, Seock-Ah Im, Sara M Tolaney, Mario Campone, Timothy Pluard
European Journal of Cancer. 2025-02-25

Lectures

The Utility of Hereditary Thrombophilia Testing Among Hospitalized Patients: A Single Center Experience
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Highlights of the 2011 San Antonio Breast Cancer Symposium
Washington University School of Medicine, Saint Louis, Missouri - 2/11/2012

Press Mentions

'Have Hope': Study Shows Immunotherapy Continues to Change Future of Cancer TreatmentApril 30th, 2025
The Power of Metastatic Breast Cancer Retreats with Lillie Shockney and Janie Metsker: Part 1October 28th, 2022
Saint Luke's Cancer Institute & Patient Discovery Launches Innovative Digital Advocate for Advance Care PlanningJune 10th, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Timothy J Pluard MD

Dr. Pluard is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.